Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Working Capital Changes (2024 - 2025)

Xilio Therapeutics' Other Working Capital Changes history spans 2 years, with the latest figure at $39.6 million for Q3 2025.

  • For Q3 2025, Other Working Capital Changes rose 12.86% year-over-year to $39.6 million; the TTM value through Sep 2025 reached $1.0 million, changed N/A, while the annual FY2024 figure was -$1.0 million, 52.18% down from the prior year.
  • Other Working Capital Changes for Q3 2025 was $39.6 million at Xilio Therapeutics, up from -$2.8 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $39.6 million in Q3 2025 and bottomed at -$39.7 million in Q2 2024.